Is AEON projected to rise?

**The stock of AEON Biopharma is projected to rise.** Here's the analysis to support this conclusion:

1. **Positive Price Target**: The average price target for AEON is $9, with a high of $6.00, indicating a significant upside potential from the current price. This suggests that analysts are optimistic about the stock's future performance.
2. **Strong Buy Rating**: The consensus rating is a "Strong Buy" with only 1 Buy rating, 0 Hold ratings, and 0 Sell ratings. This indicates that analysts are overwhelmingly bullish on the stock.
3. **Technical Indicators**: The stock's technical indicators show a bullish sentiment with a 5-day moving average of $2.47, a 10-day moving average of $2.26, and a 50-day moving average of $1.56. The 5-day and 10-day moving averages are above the 50-day moving average, which is a bullish signal as it suggests that the stock is currently experiencing short-term upward momentum.

|Ticker|Name|50-Day Moving Average|5-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|AEON.A|AEON Biopharma|1.5624|2.4680|2.2580|20240724|AEON|170|

4. **Market Sentiment**: Despite the recent negative news from a disappointing interim Phase 2 results for ABP-450 in the preventive treatment of chronic migraine, the overall sentiment remains positive. The company's focus on developing ABP-450 for other indications and its safety profile may mitigate the impact of this setback.
5. **Long-Term Forecast**: The long-term stock forecast for AEON Biopharma suggests that the stock could reach $2.86 by 2025, with potential growth up to 62.01% by 2030. This indicates a strong potential for long-term growth.
6. **Investor Confidence**: The net fund flow into the stock was $5792.28, which is a positive sign of investor confidence. This inflow of funds can be an indicator of investor optimism about the stock's future performance.

In conclusion, the combination of a strong buy rating, positive price targets, bullish technical indicators, and positive investor sentiment all point to a projected rise in AEON Biopharma's stock price.